Certara rises after Q1 preliminary results, share repurchase program

Shares of drug development software provider Certara CERT.O rise 7.8% to $13.91

Co expects prelim Q1 revenue of $106 million, above analysts' average estimate of $104.4 million as per data compiled by LSEG

CERT expects 2025 revenue in the range of $415 million to $425 million, analysts' on average expect 2025 revenue of $419.8 million

Co says its board has authorized a $100 million share repurchase program

Separately, co launches an AI-enabled clinical assistance software to aid drug development that will reduce, refine, or replace animal testing

The move comes after the U.S. FDA said it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with "human-relevant methods," including the use of AI-based models

Including session's move, CERT up 31.2% YTD